Flossbach Von Storch SE Invests $9.09 Million in IDEXX Laboratories, Inc. $IDXX
Flossbach Von Storch SE has acquired a new stake worth $9.09 million in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter. Other institutional investors have also adjusted their holdings in the company, which recently reported strong quarterly earnings, beating analyst expectations. Analysts have a "Moderate Buy" consensus rating for IDEXX Laboratories with an average price target of $747.00.
Danske Bank A S Buys New Stake in IDEXX Laboratories, Inc. $IDXX
Danske Bank A S has acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, purchasing 47,185 shares valued at approximately $24.84 million. This acquisition makes Danske Bank A S an owner of about 0.06% of IDEXX Laboratories. Other institutional investors have also adjusted their holdings in the company, which recently reported strong earnings, beating analyst expectations with $4.27 EPS and $1.22 billion in revenue for the quarter.
Resilient IDEXX Laboratories stock trades in the mid-$550s as investors weigh premium valuation and growth outlook
IDEXX Laboratories (IDXX) stock is consolidating in the mid-$550 range, supported by strong analyst growth expectations and a high earnings multiple. Despite its premium valuation, some analysts suggest the stock could be undervalued by 22% compared to a fair value estimate of $709.14. The company's veterinary diagnostics business, driven by secular trends like increased pet ownership, underpins its robust growth outlook.
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors despite daily gains
IDEXX Laboratories Inc. (IDXX) stock gained 1.32% on Tuesday, closing at $553.32, despite a general downturn in the stock market. The S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain for IDEXX Laboratories broke a five-day losing streak for the company's stock.
IDEXX Laboratories stock holds above the mid-$540s as valuation stays demanding
IDEXX Laboratories stock is trading in the mid-$540s, with a demanding 38.4x price-to-earnings multiple, despite a negative 5-year performance but positive short-term gains. The company continues to perform well operationally, driven by strong demand for animal health diagnostics, consumables, and software. Investors are weighing the rich valuation against the company's solid growth and resilient margins, particularly as the stock sits near the lower end of its 52-week range.
IDEXX Laboratories (IDXX) Could Be 22% Undervalued As New Cardiac Test Expands Its Reach
IDEXX Laboratories (IDXX) has launched a new cardiac diagnostic test, Catalyst proBNP, expanding its offerings for companion animals amidst a period of share price decline. Despite a 17.41% year-to-date drop, the stock is considered 22% undervalued with a fair value of $709.14, driven by expectations of growth from innovative diagnostic platforms and recurring revenue. However, the company faces potential challenges from soft veterinary visit growth and slow international adoption of diagnostics.
Plato Investment Management Ltd Takes $1.48 Million Position in IDEXX Laboratories, Inc. $IDXX
Plato Investment Management Ltd initiated a new position in IDEXX Laboratories (NASDAQ:IDXX) during the second quarter, acquiring 2,836 shares valued at approximately $1.48 million. Several other institutional investors also adjusted their stakes in IDXX, with 87.84% of the stock now owned by hedge funds and institutions. The company recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts with an average target price of $747.00.
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a 26.86% Potential Upside in the Diagnostics & Research Sector
IDEXX Laboratories, Inc. (IDXX) is presented as a promising investment in the Diagnostics & Research sector, boasting a potential upside of 26.86% and a strong market position with a $43.41 billion market capitalization. The company exhibits robust financial health with a 74.21% return on equity and over $909 million in free cash flow, reinvesting profits for growth rather than dividends. Analyst sentiment is largely positive, suggesting considerable room for capital appreciation supported by its innovative product offerings and global reach.
Weekly Recap: AI diagnostics expansion and Barclays trims target to $710
IDEXX Laboratories (IDXX) is expanding its diagnostics, AI software, and product offerings, reporting strong recurring revenue growth and projecting high operating margins. Despite this positive outlook, Barclays has maintained its "Overweight" rating but adjusted its 12-month price target from $800 to $710.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts
Analysts have issued a "Moderate Buy" consensus rating for IDEXX Laboratories (NASDAQ:IDXX), with six buy ratings and four holds among ten covering brokerages. The average 12-month price target is $747, and the company recently surpassed quarterly earnings expectations with $4.27 EPS and $1.22 billion in revenue. IDEXX stock opened at $550.96, down 2.8%, and is trading below its 52-week high, with a P/E ratio of 38.75.
BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $665
BofA Securities has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) and increased its price target to $665. This adjustment reflects the firm's updated outlook on the company's financial prospects and market valuation.
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories unveiled its growth strategy at Investor Day, targeting a $45 billion pet diagnostics market. The company plans to expand its diagnostic testing through AI, new platforms like inVue Dx and MultiCue Dx, and by enhancing cancer detection panels. IDEXX aims to improve veterinary practice efficiency and pet health outcomes while projecting significant long-term financial growth.
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell 2.82% on Friday, closing at $550.96. This underperformance occurred during a generally difficult trading session for the market, with both the S&P 500 and Dow Jones Industrial Average also declining. This marks the fourth consecutive day of losses for IDEXX stock.
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IDEXX Laboratories Inc (IDXX), focusing on its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock has a momentum score of 3.37, trading between a resistance of 605.29 and support of 515.50. Technical indicators show mostly "Sell" or "Neutral" signals, with moving averages also predominantly indicating a "Sell" signal.
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell 2.74% on Wednesday, closing at $570.58. This underperformance occurred on a mixed trading day where the S&P 500 Index rose, but the Dow Jones Industrial Average slightly declined. This marks the second consecutive day of losses for IDEXX Laboratories Inc.
Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating
Barclays has updated its price target for IDEXX Laboratories (IDXX), lowering it to $710 from the previous $800. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock. This indicates a continued positive outlook on the company's performance, even with a revised valuation.
IDEXX launches in-clinic cardiac test for cats and dogs
IDEXX Laboratories Inc. has launched the Catalyst proBNP Test, an in-clinic diagnostic tool for heart disease in cats and dogs. This test measures the NT-proBNP biomarker, providing rapid quantitative results to veterinarians for screening, diagnosis, and monitoring of cardiac conditions. The test will be available in North America starting October 2026, targeting a global cardiac testing market estimated at $4 billion.
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell 1.53% on Tuesday, closing at $586.64, despite a general downturn in the stock market. The S&P 500 Index and Dow Jones Industrial Average also saw declines of 0.32% and 0.34%, respectively. The company's stock is now 23.81% below its 52-week high of $769.98, which was reached on November 26th.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a dual-species, in-clinic test for NT-proBNP, aimed at improving cardiac assessment for cats and dogs. This test provides rapid, accurate results at the point of care, helping veterinarians identify heart disease earlier and make more informed decisions, especially where specialist access is limited. The Catalyst proBNP test will be available in North America starting October 2026, expanding IDEXX's cardiac health portfolio.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, accurate quantitative cardiac assessment for cats and dogs directly at the point of care, addressing a significant need in veterinary medicine where heart disease is common but often underassessed. The Catalyst proBNP test aims to help veterinarians make quicker, more informed decisions regarding cardiac health, disease screening, diagnosis, and monitoring.
IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment
IDEXX Laboratories has introduced the Catalyst proBNP Test, designed for in-clinic assessment of cardiac disease in animals. This launch is expected to enhance veterinary diagnostics by providing rapid and accurate results. The company, a leader in veterinary diagnostics, continues to innovate in the animal health sector.
IDEXX Test Brings Heart-Disease Results for Cats and Dogs in Minutes
IDEXX Laboratories has launched the Catalyst™ proBNP Test, a new in-clinic diagnostic tool for heart disease in cats and dogs. This dual-species test provides quantitative NT-proBNP results in minutes, allowing veterinarians to assess cardiac health and make informed treatment decisions faster. The test expands IDEXX's cardiac health offerings and addresses the challenge of underassessed heart conditions in companion animals.
Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating
Barclays has updated its price target for IDEXX Laboratories (IDXX) to $710, down from the previous $800, while maintaining an "Overweight" rating on the stock. This adjustment reflects a revised valuation perspective for the veterinary diagnostics company. The news comes amid other analyst updates and recent financial reporting from IDEXX Laboratories.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories has launched the Catalyst proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, laboratory-level accurate results for assessing heart disease in cats and dogs, a condition often underdiagnosed in general practice. The Catalyst proBNP Test aims to reduce reliance on multi-step referrals and improve early detection and management of cardiac conditions in companion animals.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock rally by 1.55% to $595.76 on Monday, performing strongly despite an overall poor trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both experienced declines. IDEXX Laboratories Inc. is currently trading 22.63% below its 52-week high.
NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX
NewEdge Advisors LLC increased its stake in IDEXX Laboratories, Inc. by 60.9% in the first quarter, purchasing an additional 5,761 shares, bringing their total holdings to 15,221 shares valued at $8.55 million. The company reported strong Q1 earnings with EPS of $4.27, beating estimates, and revenue of $1.22 billion, up 9.7% year-over-year. Analysts maintain a "Moderate Buy" consensus with an average price target of $756.
Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX
Seilern Investment Management Ltd increased its stake in IDEXX Laboratories, Inc. by 20.7% in the second quarter, purchasing an additional 16,729 shares. The firm now holds 97,560 shares valued at approximately $51.4 million, making IDEXX its fifth-largest position. IDEXX Laboratories reported strong quarterly results, beating EPS and revenue estimates, and institutional investors collectively own 87.84% of the company's outstanding stock.
IDEXX Laboratories Inc (HAM:IX1) Stock Price & 30 Year Financial Data
This article provides comprehensive 30-year financial data for IDEXX Laboratories Inc (HAM:IX1), including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It details key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB Ratio, and GF Score, offering an in-depth financial overview for potential investors. The data presented covers annuals and allows for customized views and export options.
IDEXX Labs posts 9% organic growth, raises EPS forecast, driven by global diagnostic expansion.
IDEXX Laboratories reported a 9% organic revenue growth in Q2 2026 and has subsequently increased its EPS guidance to $14.69–14.94, driven by strong demand for its veterinary diagnostic products. While growth in the US market is decelerating, significant long-term potential is seen in international expansion. The company's focus on companion animal diagnostics, improved free cash flow, and capital allocation contribute to a positive outlook despite a premium valuation.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, key financial statistics, historical performance, and analyst ratings. It details the company's operations in animal diagnostics, water quality, and veterinary software, and compares its performance to benchmarks like the S&P 500 and similar companies. The content is current as of August 7, 2026, with an analyst rating update on August 5, 2026.
Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX
Aurora Investment Managers LLC. has acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX), purchasing 4,638 shares valued at approximately $2.44 million. This investment makes IDEXX Laboratories the 21st largest position in Aurora Investment Managers' portfolio, representing 1.5% of its total investments. The article also details recent activities by other institutional investors in IDXX, analyst ratings, and the company's stock performance and financial results.
What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate?
This article analyzes IDEXX Laboratories, Inc.'s stock price movements and valuation, utilizing a discounted cash flow (DCF) model to estimate its intrinsic value. It suggests the stock may be trading below its fair value, indicating potential for growth despite a recent price decline.
Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.
IDEXX Laboratories reported strong Q2 2026 earnings, beating revenue and EPS estimates, despite a decline in U.S. same-store clinical veterinary visits. The company raised its full-year guidance, driven by robust performance in its CAG Diagnostics segment and the successful rollout of its inVue Dx cytology analyzer. Although free cash flow missed estimates due to capital spending timing, TIKR's model projects a significant upside for IDXX stock, valuing it at $1,043 based on sustained diagnostics growth.
IDEXX Labs Is Maintained at Neutral by UBS
UBS has maintained its "Neutral" rating on IDEXX Labs (IDXX) stock. This indicates that the analyst believes the stock will perform in line with the market. No specific financial data or price targets were provided in this brief announcement.
IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary
IDEXX Laboratories reported strong financial results for the quarter ended 2026, with revenue of $1.22 billion and diluted EPS of $4.27, both exceeding the prior year. The growth was driven by higher volumes and prices in core segments, particularly recurring diagnostics and reference lab testing. Gross margin expanded due to product mix and productivity, despite increased investments in sales, marketing, and R&D.
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories (NASDAQ: IDXX) stock rose on Tuesday after the company reported strong second-quarter results that exceeded Wall Street estimates and subsequently raised its full-year earnings outlook for 2026. The growth was primarily driven by its Companion Animal Diagnostics segment, despite a slight decline in U.S. same-store clinical visits. Analysts remain positive on IDEXX's prospects, highlighting its strong competitive position and potential for future growth catalysts.
Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792
Jefferies has increased its price target for IDEXX Laboratories (IDXX) to $795 from the previous $792, while maintaining a Hold rating on the stock. This adjustment reflects a modest change in the firm's outlook for the company.
Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650
Citigroup has raised its price target for IDEXX Laboratories (IDXX) from $650 to $670, as reported on August 5, 2026. This adjustment follows other recent analyst updates for the company, including Jefferies increasing its target to $795 and UBS raising its target to $670. The company, a leader in veterinary diagnostics, also recently updated its earnings guidance for 2026.
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670
UBS has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) and increased its price target to $670. This adjustment reflects the firm's updated valuation for the company.
Citi Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670
Citi has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) while simultaneously increasing its target price for the company to $670. This adjustment indicates a continued cautious yet optimistic outlook on the stock's future performance.
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside
Analysts have raised the average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock to $719, up from $711.64, with a range between $620 and $805. This new target suggests a potential upside of approximately 27% from its Aug. 3 closing price. The consensus rating among 17 analysts remains a "Buy," with 9 Buys, 7 Holds, and 1 Sell recommendation.
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating
William Blair has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US). This continued endorsement reflects a positive outlook from the firm regarding the company's performance and prospects.
IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ)
IDEXX Laboratories (IDXX) shares rose over 5% after the company reported strong second-quarter results and provided upbeat full-year earnings guidance. The veterinary diagnostics company posted an adjusted EPS of $4.07 for the quarter. This positive performance has led to a significant increase in its stock price during Tuesday afternoon trading.
IDEXX Laboratories Q2 2026 Earnings Call Transcript
IDEXX Laboratories reported strong Q2 2026 financial results, with a 10% revenue increase and a raised full-year outlook. The company highlighted robust growth in CAG Diagnostics, Water, and LPD businesses, driven by innovation, increased diagnostic utilization, and expanding customer
IDEXX Laboratories Announces Second Quarter Results
IDEXX Laboratories reported strong second quarter 2026 results, with revenue growth of 10% and EPS increasing by 18%. The company's Companion Animal Group Diagnostics recurring revenue grew by 11%, driven by innovation and increased diagnostic utilization. IDEXX also narrowed its 2026 revenue guidance and raised its EPS outlook, reflecting strong operational performance despite some foreign exchange headwinds.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
Idexx Laboratories (IDXX) reported strong Q2 2026 earnings, beating Zacks Consensus Estimates for both earnings per share ($4.27 vs. $3.95) and revenues ($1.22 billion vs. $1.20 billion). The company has consistently surpassed analyst expectations over the past four quarters. Despite the positive results, Idexx shares have underperformed the S&P 500 year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
IDEXX Labs earnings beat by $0.31, revenue topped estimates
IDEXX Labs (NASDAQ: IDXX) reported strong Q2 results, with EPS of $4.27 surpassing analyst estimates by $0.31 and revenue reaching $1.22 billion, exceeding the consensus. The company also provided optimistic FY 2026 guidance, projecting EPS between $14.69 and $14.94 and revenue of $4.70 billion to $4.75 billion, both above current analyst consensus. Despite recent stock price fluctuations, the earnings report indicates positive performance.
Earnings Flash (IDXX) IDEXX Laboratories Posts Q2 Adjusted EPS $4.07, vs. FactSet Est of $3.94
IDEXX Laboratories (IDXX) announced its Q2 adjusted earnings per share (EPS) of $4.07, surpassing the FactSet estimate of $3.94. The company also reported increased Q2 comparable earnings and revenue, and provided an updated 2026 outlook. IDEXX Laboratories is a global leader in diagnostic instruments for animal health and water analysis.
Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q2 Revenue $1.22B, vs. FactSet Est of $1.20B
IDEXX Laboratories, Inc. (IDXX) reported strong second-quarter results, with revenue reaching $1.22 billion, surpassing FactSet's estimate of $1.20 billion. The company also announced adjusted EPS of $4.07, exceeding the FactSet estimate of $3.94. This positive earnings flash highlights IDEXX's continued growth in the medical equipment, supplies, and distribution sector.
IDEXX Labs stock rises nearly 4% on earnings beat and raised guidance
IDEXX Laboratories Inc. reported strong second-quarter results, exceeding analyst expectations for both adjusted EPS and revenue. The company also raised its full-year 2026 EPS guidance, leading to a nearly 4% rise in its stock during pre-market trading. Key drivers included the "Technology for Life" strategy and significant growth in Companion Animal Group Diagnostics recurring revenue.
